Your browser is no longer supported. Please, upgrade your browser.
MCRB Seres Therapeutics, Inc. daily Stock Chart
MCRB [NASD]
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own0.30% Shs Outstand69.82M Perf Week0.28%
Market Cap245.77M Forward P/E- EPS next Y-0.90 Insider Trans-1.60% Shs Float62.79M Perf Month0.00%
Income-72.80M PEG- EPS next Q-0.28 Inst Own82.50% Short Float7.56% Perf Quarter-8.93%
Sales37.50M P/S6.55 EPS this Y-9.90% Inst Trans1.67% Short Ratio22.06 Perf Half Y-6.38%
Book/sh-0.46 P/B- EPS next Y29.70% ROA-58.50% Target Price8.67 Perf Year-40.34%
Cash/sh1.20 P/C2.93 EPS next 5Y- ROE173.20% 52W Range2.02 - 8.39 Perf YTD2.03%
Dividend- P/FCF- EPS past 5Y-67.50% ROI208.90% 52W High-59.95% Beta1.83
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low66.34% ATR0.25
Employees145 Current Ratio2.10 Sales Q/Q-23.10% Oper. Margin- RSI (14)40.07 Volatility8.47% 7.17%
OptionableYes Debt/Eq- EPS Q/Q56.40% Profit Margin- Rel Volume0.60 Prev Close3.52
ShortableYes LT Debt/Eq- EarningsMar 04 BMO Payout- Avg Volume215.25K Price3.36
Recom2.00 SMA20-4.72% SMA50-6.91% SMA200-3.62% Volume86,628 Change-4.55%
Apr-30-19Initiated Jefferies Hold $7
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
Jul-22-15Initiated Canaccord Genuity Buy $50
Jul-21-15Initiated Leerink Partners Outperform
Jul-21-15Initiated Goldman Neutral
Jul-21-15Initiated BofA/Merrill Neutral
Feb-25-20 07:00AM  Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020 Business Wire
Jan-17-20 08:26AM  Did You Manage To Avoid Seres Therapeutics's (NASDAQ:MCRB) Painful 66% Share Price Drop? Simply Wall St.
Dec-20-19 05:04PM  Hedge Funds Are Dumping Seres Therapeutics Inc (MCRB) Insider Monkey
Dec-19-19 08:00AM  Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire
Dec-16-19 07:00AM  Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors Business Wire
Nov-18-19 12:21PM  How Does Investing In Seres Therapeutics, Inc. (NASDAQ:MCRB) Impact The Volatility Of Your Portfolio? Simply Wall St. -5.43%
Nov-14-19 07:00AM  Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference Business Wire
01:55AM  Edited Transcript of MCRB earnings conference call or presentation 5-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 08:35AM  Seres Therapeutics (MCRB) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.84%
07:00AM  Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update Business Wire
Oct-31-19 04:00PM  Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019 Business Wire
Sep-19-19 03:26PM  What's The Cash Runway For Seres Therapeutics, Inc. (NASDAQ:MCRB)? Simply Wall St.
Aug-22-19 10:01AM  Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue? Zacks
Aug-14-19 12:33PM  Edited Transcript of MCRB earnings conference call or presentation 6-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 06:38AM  Microbiome biotechs grapple with how to protect their IP American City Business Journals
Aug-06-19 04:23PM  Seres Therapeutics Inc (MCRB) Q2 2019 Earnings Call Transcript Motley Fool -6.15%
08:45AM  Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM  Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update Business Wire
07:00AM  Seres Therapeutics Appoints Stephen Berenson to its Board of Directors Business Wire
06:00AM  Seres Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-19 10:34AM  Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -7.00%
Jun-22-19 09:05AM  Do Directors Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares? Simply Wall St.
08:59AM  What Kind Of Shareholders Own Seres Therapeutics, Inc. (NASDAQ:MCRB)? Simply Wall St.
Jun-19-19 07:00AM  Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation Business Wire
Jun-17-19 09:37AM  Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms PR Newswire +7.46%
Jun-13-19 09:23PM  Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Business Wire -13.72%
07:44AM  The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
Jun-12-19 04:07PM  Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire +6.84%
May-29-19 04:00PM  Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-08-19 01:29AM  Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-02-19 09:25AM  Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates Zacks -12.44%
08:12AM  Seres Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update Business Wire
06:30AM  Seres Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-19 04:00PM  Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019 Business Wire -5.44%
Apr-26-19 04:26PM  Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer Investor's Business Daily +6.06%
Apr-02-19 08:00AM  Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting Business Wire
Mar-23-19 08:10AM  Edited Transcript of MCRB earnings conference call or presentation 6-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 08:45AM  Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher Zacks +5.87%
Mar-11-19 02:24PM  Seres Therapeutics Options Volume Peaks After AstraZeneca News Schaeffer's Investment Research +24.85%
01:41PM  Here's Why Seres Therapeutics Stock Soared Today Motley Fool
12:58PM  Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment American City Business Journals
09:30AM  Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca Business Wire
Mar-06-19 12:13PM  Seres Therapeutics Inc (MCRB) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates Business Wire
Mar-05-19 04:00PM  Seres Therapeutics to Present at Three Upcoming March Conferences Business Wire
Mar-04-19 07:00AM  Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019 Business Wire
Feb-07-19 09:00AM  Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets Business Wire
Jan-15-19 07:00AM  Seres Therapeutics Announces Chief Executive Officer Transition Business Wire
Jan-04-19 02:29PM  Does Seres Therapeutics, Inc.s (NASDAQ:MCRB) CEO Salary Compare Well With Others? Simply Wall St. +7.60%
Jan-03-19 07:00AM  Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis Business Wire +6.21%
Nov-28-18 08:35AM  Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.28%
Nov-19-18 11:31PM  Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 07:00AM  Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference Business Wire -5.41%
Nov-08-18 09:00AM  Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates Zacks +9.77%
07:00AM  Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates Business Wire
Nov-05-18 07:00AM  Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018 Business Wire
Oct-22-18 07:00AM  Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer Business Wire
Oct-18-18 08:15AM  New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-16-18 08:12AM  Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks +9.11%
Oct-03-18 07:00AM  Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018 Business Wire
Aug-24-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Seres Therapeutics, Barnes & Noble, Carbo Ceramics, BioLife Solutions, CareDx, and Syntel New Research Emphasizes Economic Growth GlobeNewswire
Aug-14-18 10:07AM  The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team PR Newswire
Aug-03-18 09:14PM  Edited Transcript of MCRB earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:10AM  Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates Zacks
10:04AM  Seres Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM  Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates Business Wire
06:30AM  Seres Therapeutics Inc to Host Earnings Call ACCESSWIRE
Jul-25-18 04:27PM  Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018 Business Wire
Jun-19-18 08:30AM  Report: Exploring Fundamental Drivers Behind Diamondback Energy, Global Net Lease, Ambac Financial Group, IDACORP, Francesca's, and Seres Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-01-18 07:00AM  Seres Therapeutics to Present at Two Upcoming June Conferences Business Wire
May-29-18 10:48AM  3 Cheapest Stocks With Greatest Potential for Growth InvestorPlace
May-17-18 07:00AM  Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018 Business Wire -5.22%
May-10-18 03:46AM  Edited Transcript of MCRB earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 07:05AM  Seres Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates Business Wire
May-07-18 07:00AM  Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018 Business Wire
May-04-18 07:00AM  Seres Therapeutics to Present at Two Upcoming May Conferences Business Wire
Apr-25-18 08:15AM  New Research Coverage Highlights BWX Technologies, Sparton, Mercury General, Seres Therapeutics, Caleres, and GCP Applied Technologies Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-17-18 12:00PM  Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting Business Wire +9.91%
Mar-09-18 08:11AM  Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
07:00AM  Seres Therapeutics to Present at Two Upcoming March Conferences Business Wire
Mar-08-18 07:00AM  Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates Business Wire
06:15AM  Seres Therapeutics Inc to Host Earnings Call ACCESSWIRE
Mar-02-18 07:00AM  Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018 Business Wire
Feb-26-18 07:40AM  Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-31-18 07:01AM  Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer Business Wire
Jan-04-18 07:00AM  Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
07:00AM  Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis Business Wire
Dec-26-17 11:46AM  ETFs with exposure to Seres Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:32AM  Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-20-17 07:22AM  Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017 Capital Cube
Dec-19-17 07:50AM  Report: Exploring Fundamental Drivers Behind Allstate, Ashford Hospitality Prime, S&P Global, Enzo Biochem, Seres Therapeutics, and HFF New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-04-17 08:28AM  Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy MarketWatch
07:00AM  Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis Business Wire
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
06:20AM  Seres teams up with MD Anderson to explore gut's role in drug response American City Business Journals
06:00AM  Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology Business Wire
Nov-13-17 06:31PM  Edited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-08-17 04:00PM  Seres Therapeutics to Participate in Three Upcoming November Conferences Business Wire
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chapman MarcusSee RemarksNov 22Sale3.913,40013,2978,600Nov 25 04:32 PM
Chapman MarcusSee RemarksNov 01Option Exercise0.0012,000012,000Nov 25 04:32 PM
AFEYAN NOUBARDirectorJun 18Buy2.258,888,88819,999,9984,444,444Jun 20 04:17 PM